Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone

Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone

Purpose: Giant cell tumor of bone (GCTB) is a local aggressive bone tumor, histologically classified as intermediate malignancy. Recently, the RANKL inhibitor, denosumab, was developed as a novel and effective treatment option for GCTB. Since the risk of preoperative use of denosumab with curettage...

Full description

Bibliographic Details
Main Authors: Kei Sano, Yoshiyuki Suehara, Taketo Okubo, Keita Sasa, Taisei Kurihara, Keisuke Akaike, Daisuke Kubota, Tomoaki Torigoe, Nobuhiko Hasegawa, Midori Ishii, Yasuhiro Nakamura, Youngji Kim, Tatsuya Takagi, Kazuo Kaneko, Takuo Hayashi, Tsuyoshi Saito
Format: Article
Language:English
Published: SAGE Publishing 2020-06-01
Series:Journal of Orthopaedic Surgery
Online Access:https://doi.org/10.1177/2309499020929786

Internet

https://doi.org/10.1177/2309499020929786

Similar Items